Watchlist

Watchlist
Argos Therapeutics, Inc. (ARGS)
Argos Therapeutics, Inc. (ARGS)
Biotech Analysis Central Pharma News: Biogen's Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Biogen Makes A Large Deal With Ionis For Neurological Disorder Treatments News: Recently, Biogen ( BIIB ) made a deal with Ionis Pharmaceuticals…
3 Things In Biotech, April 21: Solid Stands, Argos Stops, NewLink Strives
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a…
Your Daily Pharma Scoop: Adamas Update, Shire Bidding War, Novartis Results
Analysis focus: Adamas Today, we will discuss Adamas Pharmaceuticals (ADMS), which is up sharply after reporting final results from the two-year phase 3 study of GOCOVRI in Parkinson's Disease ((PD)) patients who have dyskinesia because of long-term levodopa usage. GOCOVRI was approved…
Midday Gainers / Losers (04/19/2018)
Gainers: ECOM +20% . OPGN +18% . EBIO +17% . EYPT +15% . BPTH +14% . PRAN +13% . CCRC +13% . DXR +11% . ZYNE +11% . DEST +9% . More news on: ChannelAdvisor Corp, OpGen, Eleven Biotherapeutics, Inc., Stocks on the move, , Read more …
Premarket Losers as of 9:05 am (04/19/2018)
ARGS -67% as bails on late-stage study of Rocapuldencel-T in kidney cancer. More news on: Argos Therapeutics, Inc., Aceto Corporation, Helios and Matheson Analytics, Inc., Stocks on the move, , Read more …
Argos Therapeutics bails on late-stage study of Rocapuldencel-T in kidney cancer; shares down 64%
Nano cap Argos Therapeutics (NASDAQ: ARGS ) craters 64% premarket on increased volume in response to its announcement that it will terminate its Phase 3 ADAPT trial assessing lead candidate Rocapuldencel-T, combined with sunitinib/standard-of-care, in newly diagnosed patients w…
Argos Therapeutics reports Q4 results
Argos Therapeutics (NASDAQ: ARGS ): Q4 EPS of -$0.38 More news on: Argos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
Premarket Gainers as of 9:05 am (02/15/2018)
MBRX +48% on major breakthrough to develop a new cancer treatment. More news on: Moleculin Biotech, Inc., Argos Therapeutics, Inc., AMAG Pharmaceuticals, Inc., Stocks on the move, , Read more …
Argos Therapeutics (ARGS) Presents On Optimized Administration Sequence And Timing Of Active Dendritic Cell Immunotherapy With A PD1 Checkpoint Inhibi
The following slide deck was published by Argos Therapeutics, Inc. in conjunction with this Read more …
Premarket Losers as of 9:05 am (2/7/2018)
MTSI -18% on Q1 earnings . More news on: MACOM Technology Solutions Holdings, Inc., Chipotle Mexican Grill, Inc., Trivago, Stocks on the move, , Read more …
Argos Therapeutics, Inc. (ARGS)